Skip to main content

CORRECTION article

Front. Oncol. , 07 June 2022

Sec. Thoracic Oncology

Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.889996

Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study

This article is a correction to:

  1. Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study

    1. Read original article
Mark M. Awad*Mark M. Awad1*Yvan Le BruchecYvan Le Bruchec2Brian LuBrian Lu2Jason YeJason Ye3Julie Ann MillerJulie Ann Miller2Patrick H. LizottePatrick H. Lizotte4Megan E. CavanaughMegan E. Cavanaugh4Amanda J. RodeAmanda J. Rode4Calin Dan DumitruCalin Dan Dumitru2Alexander SpiraAlexander Spira5
  • 1Lowe Center for Thoracic Oncology and Dana-Farber Cancer Institute, Boston, MA, United States
  • 2Bristol Myers Squibb, Princeton, NJ, United States
  • 3Acetylon Pharmaceuticals, Inc, Boston, MA, United States
  • 4Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, United States
  • 5Virginia Cancer Specialists (VCS) Research Institute, Fairfax, VA, United States

A Corrigendum on
Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study

By Awad MM, Le Bruchec Y, Lu B, Ye J, Miller J, Lizotte PH, Cavanaugh ME, Rode AJ, Dumitru CD and Spira A (2021). Front. Oncol. 11:696512. doi: 10.3389/fonc.2021.696512

Angeliki Zarotiadou was not included in the Acknowledgments section in the published article. The corrected Acknowledgments section appears below.

“The authors thank the patients who participated in the study and their families. Additional thanks to Precision for Medicine, formerly ApoCell, for serum cytokine and blood immunophenotyping. Biostatistics assistance was provided by Angeliki Zarotiadou, MSc. Writing assistance was provided by Aaron Runkle, PhD, CMPP, of MediTech Media, Ltd, and funded by Bristol Myers Squibb. The authors presented these results in an abstract and poster at the 2019 ASCO Annual Meeting; May 31-June 4, 2019; Chicago, IL (40)”.

In the original article, the reference for NCCN Guidelines® for NSCLC V.1.2021 was incorrectly written in the in-text citation as “[Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCL V.1.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed (December 3, 2020). To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way]”.

It should be “[Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC V.1.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed (July 20, 2021). To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way]”.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: ACY-241, citarinostat, nivolumab, non-small cell lung cancer, HDAC6

Citation: Awad MM, Le Bruchec Y, Lu B, Ye J, Miller JA, Lizotte PH, Cavanaugh ME, Rode AJ, Dumitru CD and Spira A (2022) Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study. Front. Oncol. 12:889996. doi: 10.3389/fonc.2022.889996

Received: 04 March 2022; Accepted: 02 May 2022;
Published: 07 June 2022.

Edited and reviewed by:

Karen L. Reckamp, Cedars-Sinai Medical Center, United States

Copyright © 2022 Awad, Le Bruchec, Lu, Ye, Miller, Lizotte, Cavanaugh, Rode, Dumitru and Spira. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Mark M. Awad, TWFya19Bd2FkQGRmY2kuaGFydmFyZC5lZHU=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

Man ultramarathon runner in the mountains he trains at sunset

95% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more